Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.

Cancer biology & therapy - 1 Sept 2014

Etnyre Deven, Stone Amanda L, Fong Jason T, Jacobs Ryan J, Uppada Srijayaprakash B, Botting Gregory M, Rajanna Supriya, Moravec David N, Shambannagari Manohar R, Crees Zachary, Girard Jennifer, Bertram Ceyda, Puri Neelu

Abstract excerpt

Numerous tyrosine kinase inhibitors (TKIs) targeting c-Met are currently in clinical trials for several cancers. Their efficacy is limited due to the development of resistance. The present study aims to elucidate this mechanism of c-Met TKI resistance by investigating key mTOR and Wnt signaling proteins in melanoma cell lines resistant to SU11274, a c-Met TKI. Xenografts from RU melanoma cells treated with c-Met...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Everolimus
Share to Heterocyclic Compounds, 3-Ring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterografts

Share to Human Growth Hormone

Share to Proto-Oncogene Proteins c-met

Share to Pyrazoles

Share to Pyridazines

Share to Sirolimus

Source

Open in PubMed Open full text

Identifiers

PMID: 24914950
DOI: 10.4161/cbt.29451
PMCID: PMC4128856

Genes

BRAF
LRP6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.PMID 24914950Read ↗

Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.Semantic proximity Read ↗

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanomaSemantic proximity Read ↗

miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.Semantic proximity Read ↗

Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.Semantic proximity Read ↗

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.Semantic proximity Read ↗

Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction.Semantic proximity Read ↗

c-Met is a potentially new therapeutic target for treatment of human melanoma.Semantic proximity Read ↗

Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation.Semantic proximity Read ↗

Mechanistic insights into Rho/MRTF inhibition-induced apoptotic events and prevention of drug resistance in melanoma: Implications for the involvement of pirinSemantic proximity Read ↗

Targeting activated KIT signaling for melanoma therapy.Semantic proximity Read ↗

Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib.Semantic proximity Read ↗

c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.